| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Operating activities | ||||||||
Net loss | ||||||||
-53,202 | -47,599 | -42,462 | -35,044 | -30,168 | -24,251 | 0 | 0 | 0 |
Adjustments to reconcile net loss to cash used in operating activities: | ||||||||
Depreciation and amortization | ||||||||
1,033 | 862 | 674 | 531 | 478 | 419 | 0 | 0 | 0 |
Stock-based compensation expense | ||||||||
7,616 | 6,702 | 5,440 | 4,085 | 2,991 | 2,133 | 0 | 0 | 0 |
Accretion on investments | ||||||||
258 | 225 | 377 | 456 | 393 | 280 | 0 | 0 | 0 |
Changes in operating assets and liabilities: | ||||||||
Interest receivable on investments | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Prepaid expenses and other current assets | ||||||||
3,282 | 3,057 | 5,268 | 4,744 | 3,380 | 1,433 | 0 | 0 | 0 |
Accounts payable | ||||||||
825 | -179 | 2,145 | 1,239 | 1,602 | 2,224 | 0 | 0 | 0 |
Accrued expenses and other liabilities | ||||||||
332 | 2,137 | 2,372 | 2,603 | 2,260 | 2,450 | 0 | 0 | 0 |
Cash used in operating activities | ||||||||
-46,936 | -41,359 | -37,476 | -32,035 | -26,559 | -18,738 | 0 | 0 | 0 |
Investing activities | ||||||||
Purchases of equipment | ||||||||
4,195 | 3,879 | 3,141 | 1,188 | 839 | 1,019 | 0 | 0 | 0 |
Purchase of investments | ||||||||
87,591 | 126,261 | 188,305 | 172,033 | 171,067 | 97,810 | 0 | 0 | 0 |
Proceeds from sale or maturity of investments | ||||||||
123,523 | 109,725 | 92,490 | 59,579 | 39,309 | 22,490 | 0 | 0 | 0 |
Cash used in investing activities | ||||||||
31,737 | -20,415 | -98,956 | -113,642 | -132,597 | -76,339 | 0 | 0 | 0 |
Financing activities | ||||||||
Proceeds from the sale of Series B preferred stock, net of issuance costs | ||||||||
- | - | - | - | - | 124,830 | 0 | 0 | 0 |
Proceeds from initial public offering, net of issuance costs | ||||||||
-1,081 | 79,132 | 79,121 | 80,213 | 80,213 | 0 | 0 | 0 | 0 |
Proceeds from the exercise of stock options | ||||||||
576 | 391 | 181 | -101 | -119 | 100 | 0 | 0 | 0 |
Deferred offering costs | ||||||||
-519 | 0 | 1,198 | 2,980 | 2,641 | 1,990 | 0 | 0 | 0 |
Payment of issuance costs | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Cash provided by financing activities | ||||||||
14 | 79,523 | 78,104 | 77,112 | 82,433 | 122,940 | 0 | 0 | 0 |
Net change in cash, cash equivalents, and restricted cash | ||||||||
-15,185 | 17,749 | -58,328 | -68,565 | -76,723 | 27,863 | 0 | 0 | 0 |
Supplemental disclosure of noncash financing activities | ||||||||
Conversion of redeemable convertible preferred stock to common stock | ||||||||
0 | 259,130 | 259,130 | 259,130 | 259,130 | 0 | 0 | 0 | 0 |
Accretion of redeemable preferred stock to redemption value | ||||||||
0 | 49,900 | 53,630 | 65,220 | 76,365 | 37,298 | 0 | 0 | 0 |
Deferred offering costs included in accounts payable | ||||||||
-357 | 0 | 176 | 613 | 950 | 558 | 0 | 0 | 0 |
Property and equipment additions in accounts payable | ||||||||
118 | 270 | 205 | 888 | 6 | 14 | 0 | 0 | 0 |
Reclassification of early exercise liability upon vesting of options | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Series B redeemable convertible preferred stock | ||||||||
Accretion of redeemable preferred stock to redemption value | ||||||||
- | - | - | - | - | - | - | - | 0 |